These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7508726)

  • 1. Outcome measurement in economic evaluations of growth factors.
    Jönsson B; Karlsson G
    Eur J Cancer; 1993; 29A Suppl 7():S19-22. PubMed ID: 7508726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy.
    Peroutka JA; Mutnick AH
    Formulary; 1995 Jul; 30(7):394-5, 400-4. PubMed ID: 10151731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using filgrastim efficiently.
    Dranitsaris G
    Pharmacoeconomics; 1996 May; 9(5):466-8. PubMed ID: 10161379
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.
    Glaspy JA; Bleecker G; Crawford J; Stoller R; Strauss M
    Eur J Cancer; 1993; 29A Suppl 7():S23-30. PubMed ID: 7508727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
    Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodological issues in economic assessments of new therapies. The case of colony-stimulating factors.
    Drummond M; Menzin J; Oster G
    Pharmacoeconomics; 1994; 6 Suppl 2():18-26. PubMed ID: 10155592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
    Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myeloid growth factors. New indications with many questions].
    Palmblad J; Samuelsson J; Glimelius B; Ljungman P; Nilsson PG
    Lakartidningen; 1994 Jul; 91(28-29):2675-8. PubMed ID: 7519704
    [No Abstract]   [Full Text] [Related]  

  • 10. Health care outcomes case study: Febrile neutropenia.
    Holdsworth MT; Duncan MH
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S15-8. PubMed ID: 8846241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost considerations in therapy with myeloid growth factors.
    Glaspy JA; Jakway J
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cancer and neutropenia database study.
    Hewitt A
    Can J Oncol; 1994 Jul; 4(3):277-84. PubMed ID: 7529629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.
    Frampton JE; Faulds D
    Pharmacoeconomics; 1996 Jan; 9(1):76-96. PubMed ID: 10161371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. My conscience, your money.
    Post SG; Fleck L
    Hastings Cent Rep; 1995; 25(5):28; discussion 28-9. PubMed ID: 8530266
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.
    Lee SM; Radford JA; Dobson L; Huq T; Ryder WD; Pettengell R; Morgenstern GR; Scarffe JH; Crowther D
    Br J Cancer; 1998 Apr; 77(8):1294-9. PubMed ID: 9579836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.
    McQuaker IG; Hunter AE; Pacey S; Haynes AP; Iqbal A; Russell NH
    J Clin Oncol; 1997 Feb; 15(2):451-7. PubMed ID: 9053465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Big cost savings from small filgrastim unit doses.
    Sinsabaugh DK; Freyer DR
    Am J Hosp Pharm; 1993 Jul; 50(7):1363-4. PubMed ID: 7689787
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.
    Lyman GH
    Eur J Cancer; 2000 Apr; 36 Suppl 1():S15-21. PubMed ID: 10785605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer.
    Riikonen P; Rahiala J; Salonvaara M; Perkkiö M
    Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.